HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meirhaeghe, A. Articles by Dallongeville, J. Search for Related Content PubMed PubMed Citation Articles by Meirhaeghe, A. Articles by Dallongeville, J. Social Bookmarking                What's this?

Association Between Peroxisome Proliferator–Activated Receptor Haplotypes and the Metabolic Syndrome in French Men and Women

¹ INSERM U508, Institut Pasteur de Lille, Lille, France
² Université de Lille 2, Lille, France

	ABSTRACT

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 
We assessed the association of four polymorphisms (promoter P3 –681C>G, P2 –689C>T, Pro12Ala, and 1431C>T) in peroxisome proliferator–activated receptor (PPAR) with the metabolic syndrome risk in a large, French population study (n = 1,155). In this sample, 279 men and women presented with metabolic syndrome according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) criteria. When taken individually, none of the polymorphisms was significantly associated with the metabolic syndrome. Haplotype analyses, in contrast, revealed a significant enrichment of the GTGC haplotype frequency (corresponding to the P3 –681C>G, P2 –689C>T, Pro12Ala (C/G), and 1431C>T polymorphisms in this order) among those with metabolic syndrome compared with control subjects. Compared with the most common CCCC haplotype, the adjusted odds ratio (OR) (95% CI) of the metabolic syndrome for bearers of the GTGC haplotype was 2.37 (1.42–3.95; P = 0.002), 1.92 (1.00–3.72; P = 0.05), and 2.47 (1.09–5.62; P = 0.045) in the whole sample of men and women, respectively. Similar results were obtained when using another haplotype (GCCC, GTGT, CCCT, or GCCT) as a reference. Furthermore, when the GTGC haplotype frequency was tested alone (i.e., versus the frequency of the five other haplotypes together), the OR (95% CI) of the metabolic syndrome was 2.30 (1.05–5.00; P = 0.022). These data show that only the frequency of the GTGC haplotype was different between subjects with and without metabolic syndrome. Further analyses stratified on the 1431C>T single nucleotide polymorphism (SNP) indicated that the rare alleles of the P2 –689C>T and Pro12Ala SNPs were associated with an increased risk of the metabolic syndrome when combined to the 1431CC genotype. In conclusion, a specific haplotype of PPAR polymorphisms is associated with an increased risk of the metabolic syndrome in a French general population.

Abbreviations: PPAR, peroxisome proliferator–activated receptor ; SNP, single nucleotide polymorphism

The metabolic syndrome is a complex disorder (1) characterized by the clustering of several metabolic diseases, such as abdominal obesity, insulin resistance, elevated plasma triglyceride levels, low HDL cholesterol, high blood pressure, and altered glucose homeostasis. In adults, the metabolic syndrome prevalence ranges between 15 and 25%. Environmental factors such as low physical activity and inappropriate dietary habits are strong determinants of the metabolic syndrome. In addition, genetic factors also contribute to the individual susceptibility to the metabolic syndrome (2).

Many studies have investigated the associations between genetic polymorphisms and the various components of the metabolic syndrome. Very few, in contrast, have explored this association with the metabolic syndrome as an entity, i.e., defined according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (3), the World Health Organization (4), the European Group for the Study of Insulin Resistance (5), or the International Diabetes Federation criteria (6). The later investigations have reported significant associations between the metabolic syndrome and polymorphisms in the lamin A/C (7), the peroxisome proliferator–activated receptor (PPAR) (8), the angiotensinogen-1–converting enzyme (9,10), the LDL-related protein-associated protein 1 (11), and the ß₂-adrenergic receptor (12) genes.

PPAR is a nuclear receptor implicated in adipocyte differentiation orchestration, fatty acid metabolism, and insulin sensitization and is therefore a good candidate gene for the metabolic syndrome. Loss-of-function mutations of PPAR confer an extreme phenotype of partial lipodystrophy, early-onset severe insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and hepatic steatosis (rev. in 13). Many studies explored the association between the Pro12Ala polymorphism in PPAR and obesity, insulin sensitivity, and type 2 diabetes (rev. in 14). It appears that the Ala12 allele confers modest protection against the onset of type 2 diabetes and is also associated with an increased BMI in overweight individuals. In view of reported contradictory associations between PPAR polymorphisms and obesity and diabetes, we thought to evaluate the possible association between several polymorphisms in PPAR and the metabolic syndrome in a large, French, population-based study (n = 1,155). Four PPAR polymorphisms were tested: the promoter P3 –681C>G, P2 –689C>T, Pro12Ala, and 1431C>T in individual and haplotype analyses.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 
Participants were recruited within the framework of the WHO-MONICA (World Health Organization Multinational Monitoring of Trends and Determinants in Cardiovascular Disease) population survey conducted from 1995 to 1997 in the urban community of Lille in the north of France. The sample included subjects aged 35–64 years, randomly selected from the electoral rolls to obtain 200 participants for each sex and 10-year age-group (15,16). A total of 601 men and 594 women were recruited. To our knowledge, no individuals were related. The ethical committee of Lille University Hospital (Centre Hospitalier Régoinale Universitaire de Lille) approved the protocol.

After signing an informed consent, participants were administered a standard questionnaire, and physical measurements were made by a trained nurse. The level of physical activity was defined as walking or riding 15 min/day and/or lifting or carrying heavy objects at work daily and/or doing sports or physical exercise >2 h/week. Current cigarette smokers were defined as subjects reporting at least one cigarette per day. Total alcohol intake was expressed as the sum of millileters of alcohol per week from wine, beer, cider, and spirits.

The anthropometric measurements included body weight and waist and hip circumferences. BMI was calculated according to the Quetelet equation. Blood pressure was measured on the right arm, with the subject in a sitting position and after a minimum 5-min rest, using a standard mercury sphygmomanometer. The mean value of two consecutive blood pressure readings was taken into account.

The metabolic syndrome was defined, according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) recommendations (3), by the presence of at least three or more of the following abnormalities: waist girth >102 cm in men or >88 cm in women, triglycerides 1.50 g/l or lipid-lowering treatment, HDL cholesterol <40 mg/dl in men or <50 mg/dl in women, blood pressure 130/85 mmHg or treatment with blood pressure–lowering medications, and fasting glucose 1.10 g/l or treatment for diabetes.

Laboratory methods.
A blood sample of 20 ml was drawn on disodium EDTA after the subjects had fasted for at least 10 h. Lipid and lipoprotein levels were measured in a central laboratory (Purpan Hospital Biochemical Laboratory, Toulouse, France). The quality of biological measures was assessed within the framework of the MONICA Project. Glucose was measured by the glucose oxidase method (DuPont Dimension). Serum triglyceride levels were enzymatically measured (DuPont Dimension). HDL cholesterol was measured after sodium phosphotungstate/magnesium chloride precipitation (Boehringer Mannheim, Mannheim, Germany).

Genotyping.
The genotyping method for the PPAR polymorphisms has been described elsewhere: P3 –681C>G (17), P2 –689C>T (18), Pro12Ala (19), and 1431C>T (20).

Statistical methods.
² analysis was used to compare genotype and allele distributions between groups. Logistic regression analysis was used to calculate the odds ratio (OR) of the metabolic syndrome associated with a given polymorphism. Adjustment variables were age, alcohol, smoking, and physical activity in analyses in men and women separately or further adjusting on sex in combined men and women analyses. The dominant and recessive models were tested. Analyses were performed with the SAS statistical software release 8 (SAS Institute, Cary, NC). Haplotype analyses were based on the maximum likelihood model described in (21) and linked to the SEM algorithm (22) and performed using the software developed by the Institut National de la Santé et de la Recherche Médicale (INSERM U525), Paris, France.

	RESULTS

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 
Table 1 describes the clinical characteristics of the population studied. Table 2 shows the genotype frequencies in the metabolic syndrome and control subjects for the four PPAR polymorphisms. These frequencies were not different from the expected frequencies under Hardy-Weinberg equilibrium. No significant differences could be observed between the two clinical groups, either in men, in women, or in combined men and women. The corresponding OR of the metabolic syndrome for carriers of the rare allele versus homozygotes for the common allele of the four polymorphisms (dominant model) are presented in Table 3. These ORs varied from 0.75 to 1.39 (all NS). A recessive model was also tested, but no more significant OR could be observed (data not shown).

View this table: [in this window] [in a new window]   TABLE 2 Genotype frequencies of the PPAR polymorphisms in individuals with and without metabolic syndrome

View this table: [in this window] [in a new window]   TABLE 3 ORs of the metabolic syndrome according to PPAR polymorphisms

It appeared from Table 4 that the presence of the C1431 allele was necessary to observe a deleterious effect of the rare alleles of the –681C>G, –689C>T, and Pro12Ala SNPs on the metabolic syndrome. Because these three SNPs were in complete linkage disequilibrium, we then analyzed the individual impact of these SNPs on the metabolic syndrome in CC or CT subjects for the 1431C>T SNP to assess the relative contribution of each SNP (Table 5). No significant association could be observed between the –681C>G SNP and the metabolic syndrome in 1431CC or CT subjects, suggesting that the –681C>G SNP had no impact on the metabolic syndrome risk. On the contrary, a significantly higher risk of the metabolic syndrome was observed in –689T (OR 1.95 [95% CI 1.12–3.37]; P = 0.018) or Ala12 (2.48 [1.38–4.44]; P = 0.002) allele bearers if they also carried the 1431CC genotype. No such association was observed in 1431CT bearers.

	DISCUSSION

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

In the present study, there was no evidence of a significant impact of individual polymorphisms of PPAR on the metabolic syndrome risk. In contrast, in the Danish MONICA survey, Frederiksen et al. (8) have found a borderline statistical association between the homozygous Ala/Ala genotype and the metabolic syndrome defined according to the European Group for the Study of Insulin Resistance criteria (294 case/1,951 control subjects). However, this association was based on a very limited number of homozygous Ala12Ala subjects (n = 2), which may hamper the interpretation of the data. In the present study, analyses with the Pro12Ala polymorphism using a recessive model and the European Group for the Study of Insulin Resistance criteria (data not shown) revealed no association between PPAR Pro12Ala polymorphism and the metabolic syndrome, suggesting that early findings may be spurious. To our knowledge, there has been no other analysis of the relationship between PPAR SNPs and the metabolic syndrome. Therefore, additional studies are needed to confirm these data.

Haplotype analyses, in contrast, revealed an association between the GTGC haplotype and the metabolic syndrome in both men and women. Further analyses stratifying for the 1431C>T SNP indicated that the P2 –689T and Ala12, but not the P3 –681G rare alleles, accounted for the increased metabolic syndrome risk when present on the 1431CC background. This result is consistent with a previous study (23) that has shown that the Ala12Ala genotype conferred an increased risk of type 2 diabetes when associated with the 1431CC genotype but not the 1431TT genotype. Our study further extends this analysis to the P3 –681C>G and P2 –689C>T SNPs. Other studies (24), in contrast, have reported higher BMI in women carrying both the homozygous Ala12Ala and 1431TT genotypes compared with Pro12Pro/1431CC women. Similarly, the Ala12-1431C haplotype was associated with lower BMI compared with Pro-1431C haplotype carriers in both diabetic and nondiabetic Scottish populations (25), and the 1431C allele conferred a protection against type 2 diabetes (26). The reasons for these discrepancies are not known. One possible explanation may be related to the selection of diabetic or obese patients as opposed to a random population-based sample. Such selection procedures may have introduced a bias in the sample. Other possible explanations may be related to the lack of sufficient statistical power. Finally, possible interactions with other genes as well as uncontrolled environmental factors such as diet may also explain the difference between studies, although these hypotheses need further analyses.

It is quite difficult to provide a potential mechanism by which a particular haplotype of PPAR could promote susceptibility to the metabolic syndrome. In rodents, supraphysiological activation of PPAR by thiazolidinediones markedly increases triglyceride content of white adipose tissue, thereby decreasing triglyceride content of liver and muscle, leading to amelioration of insulin resistance at the expense of obesity. In contrast, moderate reduction of PPAR activity by heterozygous PPAR deficiency decreases triglyceride content of white adipose tissue, skeletal muscle, and liver due to increased leptin expression and increase in fatty acid combustion and decrease in lipogenesis, thereby ameliorating high-fat diet–induced obesity and insulin resistance (27). From the human point of view, a point mutation leading to the permanent activation of PPAR is associated with severe obesity (28), whereas dominant-negative mutations in PPAR lead to a monogenic model of the metabolic syndrome in association with a stereotyped form of partial lipodystrophy (29). The metabolic syndrome we study in our sample is associated with abdominal obesity and not lipodystrophy. Therefore, the PPAR GTGC haplotype is likely to be associated with higher PPAR activity, consequently leading to higher adipocyte differentiation, which might explain the fact that the –681C>G, –689C>T, and Pro12Ala polymorphisms are associated with higher body weight and fat mass in our sample. This phenomenon, in turn, induces the storage of triglycerides conducting to insulin resistance and associated disorders (metabolic syndrome).

The present study has some strengths and limitations. It was conducted in a large random sample of population, which avoids possible bias due to recruitment in hospitals or clinics and university staff or students. We analyzed four SNPs at the same time, which offers a better biological assessment of the gene variability. Due to the high levels of linkage disequilibrium among the SNPs, haplotype analyses were performed (22), which allowed us to account for covariability. Our results showed that only the GTGC haplotype frequency was different from the frequencies of other haplotypes between subjects with and without metabolic syndrome. The analyses were performed in men and women separately, which is an important advantage with regards to the impact of sex on morphology and the metabolic syndrome. Although the frequency of the GTGC haplotype is low, the finding of consistent statistically significant associations in both men and women further supports the strength of this association. Finally, the association between PPAR haplotypes and the metabolic syndrome risk was independent of the definition of the metabolic syndrome. These results support the fact that PPAR might play a role in the occurrence of this syndrome in general populations. The major limitation of the study may be the relative small size of the sample. However, to our knowledge, this is one of the largest studies with metabolic syndrome subjects.

In conclusion, our study highlights the fact that taking into account the combination of several SNPs is essential in characterizing the phenotypic impact of PPAR. We have shown that the haplotype composed of the P2 –689T, Ala12, and 1431C alleles of PPAR enhances susceptibility to the metabolic syndrome in a large, population-based population of French men and women.

	ACKNOWLEDGMENTS

 
The WHO-MONICA population study developed in the North of France was supported by grants from the Conseil Régional du Nord-Pas de Calais, the Fondation pour la Recherche Médicale, ONIVINS, the Parke-Davis Laboratory, the Mutuelle Générale de l’Education Nationale, the Réseau National de Santé Publique, the Direction Générale de La Santé, the Institut National de la Santé Et de la Recherche Médicale (INSERM), the Institut Pasteur de Lille, and the Unité d’Evaluation du Centre Hospitalier et Universitaire de Lille.

Received for publication March 17, 2005 and accepted in revised form July 15, 2005

	REFERENCES

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Timar O, Sestier F, Levy E: Metabolic syndrome X: a review. Can J Cardiol 16:779–789, 2000[Medline]
2. Liese AD, Mayer-Davis EJ, Tyroler HA, Davis CE, Keil U, Schmidt MI, Brancati FL, Heiss G: Familial components of the multiple metabolic syndrome: the ARIC study. Diabetologia 40:963–970, 1997[Medline]
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497, 2001[Free Full Text]
4. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553, 1998[Medline]
5. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443, 1999[Medline]
6. New International Diabetes Federation worldwide definition of the metabolic syndrome. Available at http://www.idf.org/home/, 2005. Accessed 14 April 2005
7. Steinle NI, Kazlauskaite R, Imumorin IG, Hsueh WC, Pollin TI, O’Connell JR, Mitchell BD, Shuldiner AR: Variation in the lamin A/C gene: associations with metabolic syndrome. Arterioscler Thromb Vasc Biol 24:1708–1713, 2004[Abstract/Free Full Text]
8. Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA: Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 87:3989–3992, 2002[Abstract/Free Full Text]
9. Lee YJ, Tsai JC: ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care 25:1002–1008, 2002[Abstract/Free Full Text]
10. Thomas GN, Tomlinson B, Chan JC, Sanderson JE, Cockram CS, Critchley JA: Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: a significant association of the ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care 24:356–361, 2001[Abstract/Free Full Text]
11. McCarthy JJ, Meyer J, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ: Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet 114:87–98, 2003[Medline]
12. Dallongeville J, Helbecque N, Cottel D, Amouyel P, Meirhaeghe A: The Gly16–>Arg16 and Gln27–>Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocrinol Metab 88:4862–4866, 2003[Abstract/Free Full Text]
13. Gurnell M, Savage DB, Chatterjee VK, O’Rahilly S: The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 88:2412–2421, 2003[Abstract/Free Full Text]
14. Meirhaeghe A, Amouyel P: Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 83:93–102, 2004[Medline]
15. Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. The World Health Organization MONICA Project. Int J Epidemiol 23:505–516, 1994[Abstract/Free Full Text]
16. Aaronson DS, Horvath CM: A road map for those who know JAK-STAT. Science 296:1653–1655, 2002[Abstract/Free Full Text]
17. Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J, Amouyel P: A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 23:289–294, 2003[Abstract/Free Full Text]
18. Meirhaeghe A, Tanck MWT, Fajas L, Janot C, Helbecque N, Cottel D, Auwerx J, Amouyel P, Dallongeville J: Study of a new PPAR2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab 85:140–148, 2005[Medline]
19. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P: Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 24:195–199, 2000[Medline]
20. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P: A genetic polymorphism of the peroxisome proliferator-activated receptor gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435–440, 1998[Abstract/Free Full Text]
21. Tregouet DA, Barbaux S, Escolano S, Tahri N, Golmard JL, Tiret L, Cambien F: Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet 11:2015–2023, 2002[Abstract/Free Full Text]
22. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL: A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Intern Med 68:165–177, 2004
23. Evans D, de Heer J, Hagemann C, Wendt D, Wolf A, Beisiegel U, Mann WA: Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 109:151–154, 2001[Medline]
24. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M: Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84:3708–3712, 1999[Abstract/Free Full Text]
25. Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M, Montgomery HE, Boyle D, Morris A, Palmer CN: Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21, 2002[Medline]
26. Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH, Morris AD, Palmer CN: Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to type 2 diabetes. Diabetologia 47:555–558, 2004[Medline]
27. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245–41254, 2001[Abstract/Free Full Text]
28. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339:953–959, 1998[Abstract/Free Full Text]
29. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O’Rahilly S: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52:910–917, 2003[Abstract/Free Full Text]

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				J. Waden, L. M. Thorn, C. Forsblom, T. Lakka, M. Saraheimo, M. Rosengard-Barlund, O. Heikkila, M. Wessman, J. A. Turunen, M. Parkkonen, et al. Leisure-Time Physical Activity Is Associated With the Metabolic Syndrome in Type 1 Diabetes: Effect of the PPAR{gamma} Pro12Ala polymorphism: the FinnDiane Study Diabetes Care, June 1, 2007; 30(6): 1618 - 1620. [Full Text] [PDF]

				B. L. Urquhart, R. G. Tirona, and R. B. Kim Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578. [Abstract] [Full Text] [PDF]

				A. J. Gilde, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32. [Abstract] [Full Text] [PDF]

				L. Hansen, C. T. Ekstrom, R. Tabanera y Palacios, M. Anant, K. Wassermann, and R. R. Reinhardt The Pro12Ala Variant of the PPARG Gene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-{gamma}/{alpha} Agonist-Induced Edema in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3446 - 3450. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meirhaeghe, A. Articles by Dallongeville, J. Search for Related Content PubMed PubMed Citation Articles by Meirhaeghe, A. Articles by Dallongeville, J. Social Bookmarking                What's this?